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Background: The mesencephalic dopaminergic (mDA) cell system is composed of two major groups of projecting
cells in the Substantia Nigra (SN) (A9 neurons) and the Ventral Tegmental Area (VTA) (A10 cells). Selective
degeneration of A9 neurons occurs in Parkinson’s disease (PD) while abnormal function of A10 cells has been
linked to schizophrenia, attention deficit and addiction. The molecular basis that underlies selective vulnerability of
A9 and A10 neurons is presently unknown.
Results: By taking advantage of transgenic labeling, laser capture microdissection coupled to nano Cap-Analysis
of Gene Expression (nanoCAGE) technology on isolated A9 and A10 cells, we found that a subset of Olfactory
Receptors (OR)s is expressed in mDA neurons. Gene expression analysis was integrated with the FANTOM5 Helicos
CAGE sequencing datasets, showing the presence of these ORs in selected tissues and brain areas outside of the
olfactory epithelium. OR expression in the mesencephalon was validated by RT-PCR and in situ hybridization. By
screening 16 potential ligands on 5 mDA ORs recombinantly expressed in an heterologous in vitro system, we
identified carvone enantiomers as agonists at Olfr287 and able to evoke an intracellular Ca2+ increase in solitary
mDA neurons. ORs were found expressed in human SN and down-regulated in PD post mortem brains.
Conclusions: Our study indicates that mDA neurons express ORs and respond to odor-like molecules providing
new opportunities for pharmacological intervention in disease.
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Dopaminergic (DA) neurons are an anatomically and
functionally heterogeneous group of cells involved in a
wide range of neuronal network activities and behavior
[1]. Among them, mesencephalic dopaminergic neurons
(mDA) are the major source of dopamine in the brain.
They present two major groups of projecting cells: the
A9 neurons of the Substantia Nigra (SN) that form the
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unless otherwise stated.Tegmental Area (VTA) that constitute the mesocortico-
limbic pathway [2]. SN neurons are involved in regulating
voluntary movements and postural reflexes while VTA
cells play a fundamental role in reward and attention.
Dysfunction of DA neurons has been implicated in sev-
eral neurodegenerative and psychiatric disorders. Selective
degeneration of A9 cells leads to Parkinson’s Disease (PD)
[3], while altered function of A10 cells has been linked to
schizophrenia, attention deficit disorder and addiction [4].
These cells share many characteristics including the en-
zymatic pathways involved in dopamine synthesis, release
and metabolism. They also present common intrinsic elec-
trophysiological properties like a spontaneous pacemaker
activity when in absence of synaptic inputs.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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mDA neurons may provide crucial information on their
physiology and on the mechanisms of cell-type specific
dysfunction [5-7].
Cap Analysis of Gene Expression (CAGE) technology
was previously developed for the systematic analysis of
Transcription Start Sites (TSS)s in eukaryotic cells and
tissues [8]. It is based on sequencing cDNA copies of the
5′ends of mRNAs, of which the integrity is inferred by
the presence of their cap. These sequences—referred to
as tags—are sufficiently long to be aligned in most cases
at a single location in the genome. The first position of
this alignment identifies a base pair where transcription
is initiated defining a TSS. The number of times a given
tag is represented in a library gives an estimate of the
expression level of the corresponding transcript. Our
previous analysis with CAGE has shown that promoters
can vary in shape, with some genes having a strong pref-
erence for initiating transcription from a single genomic
position (sharp promoters), while others use a broad
collection of TSSs within a region of approximately one
hundred bases [9,10].
In the current FANTOM5 project, a modified protocol
of CAGE for high-throughput single molecule next-
generation sequencing with Helicos (hCAGE) has been
applied to a wide range of human and mouse tissues
providing an unprecedented dataset for promoter usage
analysis [11]. Although very broad, the study was limited
to samples where 1-5 μg of total RNA could be obtained.
To expand this analysis to tiny amounts of ex vivo tissue
and to the polyA− fraction of RNAs, we developed
nanoCAGE, a technology that miniaturizes the require-
ment of CAGE for RNA material to the nanogram range
and which can be used on fixed tissues [12].
NanoCAGE has been recently applied to identify the
genome-wide collection of active TSSs of the mouse
Olfactory Epithelium (OE) [13]. In this tissue the detection
of a vast repertoire of volatile compounds (odors) is ac-
complished by a large family of Olfactory Receptors (ORs),
with more than 1100 intact genes in mouse and about 350
in human. NanoCAGE revealed the map and architecture
of promoters for 87.5% of the mouse OR genes [13].
To gain further insights into the physiology and
dysfunction of mDA neurons, we have carried out laser
capture microdissection (LCM) combined with nanoCAGE
technology to profile the genes expressed in A9 and A10
DA cells.
Here we show that a repertoire of OR genes is
expressed in mDA neurons (mDA-ORs). We then dem-
onstrate that selected odor molecules stimulate recombi-
nantly expressed mDA-ORs in heterologous cells and
trigger Ca2+ signaling in isolated primary mDA neurons.
Finally, we identify several ORs that are expressed in the
human SN and down-regulated in PD.This work is part of the FANTOM5 project. Data
downloads, genomic tools and co-published manuscripts
are summarized here: http://fantom.gsc.riken.jp/5/.
Results
Identification of ORs transcripts by expression analysis of
mDA neurons
We have determined the gene expression profiles of mDA
neurons with nanoCAGE technology. To this purpose we
took advantage of transgenic mice that selectively express
green fluorescent protein (GFP) in catecholaminergic cells
under the control of tyrosine hydroxylase (TH) gene pro-
moter (TH-GFP mice) [14]. In this mouse line we can
identify the majority of mDA neurons for their GFP label-
ing. Furthermore, we can distinguish A9 neurons from
A10 for their anatomical localization. Thus, LCM and
pressure catapulting were used to harvest A9 and A10
cells after fixation with a zinc fix-based method that
assured the preservation of both tissue morphology and
RNA integrity. RNA was then used as template for nanoC-
AGE library synthesis. The complete description of A9 and
A10-specific transcriptional landscape is presented else-
where (Lazarevic D, Bertin N, Franke V, Vlachouli C,
Caiazzo M, Plessy C, Akalin A, Vatta P, Simone R, Roncaglia
P, Daub CO, Faulkner GJ, Broccoli V, Lenhard B, Carninci P,
Gustincich S: The promotorome of adult dopaminergic
neurons of the mouse Substantia Nigra identifies new
gene networks for cell conversion. Submitted).
These results have been integrated with Affymetrix-
based gene expression datasets of A9 and A10 cells
available in the laboratory [15].
Surprisingly, transcripts for OR genes have been found
expressed in mDA neurons (Additional file 1: Table S1).
Nine ORs were validated with RT-PCR from ventral
midbrain (MB) with the appropriate controls (Figure 1a).
Cloning and sequencing of PCR products verified their
identity.
5 out of 6 ORs identified by nanoCAGE and validated
by RT-PCR display in mDA neurons a TSS very similar
if not identical to the canonical TSS found in OE [13]
(Figure 1b). OR promoters in mDA cells were of a sharp
type, with a single dominant TSS, as in the OE. Expres-
sion values, measured as number of tags per million
(TPM), ranged from 4.29 (Olfr316) to 1.3 (Olfr1288).
Since in the OE the functional activation of ORs re-
quires Gαolf and Adenyl Cyclase III (Adcy3), we monitored
their expression in our datasets showing that both signal-
ing molecules were present in A9 and A10 mDA neurons
(Additional file 2: Figure S1a). Their expression was also
detected in FANTOM5 libraries derived from mouse SN
(Additional file 2: Figure S1b).
Altogether our results indicate that OR genes as well as
components of the olfactory signaling system are expressed
in mDA neurons.
Figure 1 NanoCAGE analyses unveil atypical expression of OR genes. a) Validation of OR gene expression in mouse midbrain. MB was
dissected from C57Bl/6 mouse and total RNA extracted and used for non-quantitative PCR. Primers were designed to specifically amplify selected
ORs, as shown. RNA from OE was included as a positive control. Non-retrotranscribed (−RT) RNA was used as a negative control. Arrows indicate
OR specific bands. Data are representative of n = 3 replicas from independent tissue preparations. b) Representative tracks of nanoCAGE sequencing
data of libraries from A9 and A10 mDA neurons. Data from OE (Plessy et. al., Genome Research, [13]) are included for comparison. Genomic coordinates
are shown on top and expression values (TPM) on the right. Positive and negative TPM values indicate transcription on plus and minus DNA filament,
respectively. Black arrows in each track highlight TSS. At the bottom, annotated RefSeq is shown in grey and thick arrowheads indicate direction
of transcription.
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brain
RT-PCR and in situ hybridization experiments were then
carried out to assess mDA-ORs’ cellular distribution.2000 A9 and A10 DA neurons were harvested with
LCM in three independent experiments. As shown in
Figure 2a, expression of seven ORs was confirmed in
isolated neurons. Olfr166, Olfr287, Olfr883, Olfr1344
Figure 2 mDA-ORs are expressed in mDA neurons and in mouse brain. a) OR genes are expressed in A9 and A10 DA neurons. 2000 DA
cells were harvested by LCM. Equal numbers of non-DA cells were collected from the same brain region. OE was also included. Non-quantitative
PCR was performed with specific primers. Results are representative of n = 3 independent harvesting. b) In situ hybridization of selected mDA-ORs
in mouse DA neurons. Ventral midbrain slices were processed with Olfr287, Olfr316 and Olfr558 specific probes (green). DA neurons were visualized by
immunohistochemistry with anti-TH antibody (red). Nuclei are in blue (DAPI). Representative images of staining in A9 and A10 neurons are shown
(n = 3). Scale bars indicate 20 μm.
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whereas Olfr316 and Olfr558 were present both in A9
and in A10. For in situ hybridization (ISH) sense (nega-
tive control) and antisense riboprobes were generated
for Olfr287, Olfr316 and Olfr558 and used in a double
fluorescent experiment with anti-TH immunoreactivity
to identify DA cells [15,16] (Figure 2b). No or low back-
ground staining was measured when sense probes were
used (Additional file 3: Figure S2). Olfr287 was present
exclusively in A10 neurons, decorating a portion of
TH-positive cells in this area. Olfr316 and Olfr558
were expressed in the large majority of A9 and A10
neurons. Altogether, ISH experiments confirmed RT-PCR
data on isolated mDA cells.
We then took advantage of an antibody targeting hu-
man OR51E1 that we predicted should recognize a group
of mouse Olfrs including Olfr558, the mouse homologue
of OR51E1. First, we showed that this antibody was able
to specifically stain Olfr558-expressing cells upon full-
length cDNA transfection in HEK cells (Additional file 4:
Figure S3a). We then carried out immunostaining onbrain sections, showing that it was decorating all A9 and
A10 neurons, plus non-DA cells in the same region as well
in the cortex (Additional file 4: Figure S3b). This result
proved that OR proteins were present in MB. No signal
was detected when only the secondary antibody was used
(data not shown).
Overall these data indicate that a subset of ORs is
expressed in mDA neurons with an A9/A10 anatomical
distribution that is specific for each receptor.
mDA-ORs are expressed in mouse tissues and cells
To assess how widespread is the expression of mDA-
ORs (Olfr316, Olfr287 and Olfr558) we examined their
expression patterns in the FANTOM5 collection of
hCAGE mouse libraries (N = 395 datasets). We monitored
mDA-OR expression assessing tag counts across the
whole locus of interest (sum5end). Expression data was
represented as tag per million (TPM). We used the
decomposition-based peak identification (DPI) method to
identify peaks in CAGE profiles, taking advantage of the
deepness of sequencing and the high number of libraries
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the reference sequence annotation (Figure 3a). We detec-
ted expression of Olfr316 in bone, heart, placenta and
hippocampus (TPM ranging from 0.7 to 0.1). Olfr287 was
expressed in non-neuronal tissues such as bone (2.52
TPM) and stomach (1.07 TPM) as well as in neuronal tis-
sues such as cerebellum (TPM 1.71-4.97), striatum (TPM
0.16-4.87), cortex (TPM 3.96-4.6), medulla oblongata
(TPM 9.16-10.65) and spinal cord (TMP 17.08). Olfr558
was present in spinal cord (1.02 TPM), medulla oblongata
(0.79 TPM), cortex (0.23 TPM) and cerebellum (0.37
TPM) (Figure 3b). No expression was detected in liver,
lung, thymus, intestine and testis for any of the mDA-ORs
analyzed.
To validate the expression of Olfr316, Olfr287 an
Olfr558, we dissected several brain regions of adult
C57Bl/6 mice and carried out qRT-PCR. OE was inclu-
ded as positive control, while liver was representative of
a tissue outside of the central nervous system. All
three mDA-ORs showed a distinct pattern in the brain
(Figure 3c). Liver scored as negative for all three receptors.
Olfr287 was strongly enriched in MB as compared to the
other regions, while Olfr316 transcript was highest in the
hippocampus. Olfr558 was the only OR with the highest
expression in OE.
Recombinant mDA-ORs are activated by a subset of odors
To investigate the function of mDA-ORs in DA cells’
physiology, we first sought to identify potential agonists
for each receptor. Full-length mDA-ORs were cloned
from the ventral midbrain for Olfr166, Olfr287, Olfr316,
Olfr558 and Olfr1344 in frame with a Rho-tag sequence
at the N-terminus. cDNAs for the same receptors were
also cloned from OE and no sequence differences were
observed. Transient transfections in non-neuronal HEK
293 and in dopaminergic iMN9D cells indicated that
Olfr287, Olfr316 and Olfr1344 cloned from MB drove
the expression of a protein with the expected molecular
weight (Additional file 5: Figure S4a) and whose localization
was mainly at the plasma membrane (Additional file 5:
Figure S4b and Figure S4c). Lower expression was achieved
for Olfr166 and Olfr558 which synthesis was at detection
limits of western blot analysis but visible by immuno-
fluorescence. The well-characterized S6 OR was used in all
experiments as positive control.
For functional assays we transiently expressed mDA-
ORs in heterologous HEK 293 cells in combination with
CRE-SEAP reporter plasmid and determined ligand speci-
ficity by measuring SEAP quantity in the culture medium
in response to odors. Sixteen odor molecules were used for
ligand screening including standard odors used for ORs
de-orphanization (Additional file 6: Table S2) [17] as well
as putative ligands proposed on the basis of sequence
similarity between the ORs present in the OlfactionDB(http://molsim.sci.univr.it/OlfactionDB) and queried mDA-
ORs plus chemical ligands identified by chemoinformatic
approaches (Additional file 7: Figure S5).
Olfr287 was the only receptor showing a robust, repro-
ducible response to selected odor-like molecules (Figure 4a;
Additional file 8: Figure S6). The strongest responses were
elicited by S- and R-carvones as well as decanoic acid.
Active odors were then used at increasing concen-
trations proving their function as agonists at μM levels
(Figure 4b). Their specificity was measured in cells trans-
fected with an empty control vector (Figure 4b).
Isolated primary mDA neurons respond to odor
molecules
To assess the physiological response of DA cells to odor-
like agonists at mDA-ORs, we used ratiometric Ca2+ dy-
namics evoked by odor stimulation on isolated neurons.
Primary mDA neurons were prepared from TH-GFP
mice upon enzymatic digestion and mechanical tritur-
ation of MB. Isolated neurons were loaded with the Ca2+
indicator fura-2 AM and then were challenged with odor
mixture (Figure 4c) or a mix of carvone enantiomers
(Figure 4d). About one-third of DA neurons used for the
analysis showed Ca2+ responsiveness upon odor stimula-
tion. In particular, 29.7% were activated by odor mixture
(n = 11/37) and 31% (n = 9/29) by carvones. Pulse with
odors typically induced a fast onset of the Ca2+ signal that
lasted 1–2 min (odor mix: cells n = 11, ΔR/R0 = 80.5 ± 26;
carvone mix: n = 9, ΔR/R0 = 73 ± 14.4). Importantly, after
odor washout, DA cells showed normal Ca2+ transients to
high K+ solution, indicating that the general excitability
and downstream Ca2+ entry were intact (data not shown).
A subset of human ORs is expressed in SN and regulated
in PD post mortem brains
We then aimed to identify ORs in human SN. To this
purpose we used two unbiased approaches. First, we took
advantage of the large FANTOM5 collection of deep-
sequencing datasets [11]. These include four libraries from
SN derived from post mortem tissues of three human
adults and one neonate (Francescatto M, Vitezic M, Rizzu
P, Simon-Sanchez J, Andersson R, FANTOM Consortium,
Daub CO, Sandelin A, de Hoon MJL, Carninci P, Forrest
AR, Heutink P: A high resolution spatial-temporal pro-
moterome of the human brain. Submitted). To obtain
the coordinates of putative promoters for human ORs, we
selected windows of 200 bp centered on transcription start
sites of mouse OR genes [13] and “lifted” their coordinates
over the most recent version of annotated human genome
[18]. This analysis pulled out 19 putative coordinates in
the human genome for which transcription was evident in
any of the SN libraries. We then manually verified each
genomic position. 5 of them turned out to be artifacts, as
not corresponding to any human OR gene locus (data not
Figure 3 Expression of mouse mDA-ORs in tissues and primary
cells. a) ZENBU browser view of Olfr287, Olfr316 and Olfr558 TSS in
pooled mouse tissues. Genomic coordinates are shown on top and
scale of expression values (TPM) on the left. Positive and negative
TPM values indicate transcription on plus and minus DNA filament,
respectively. Black arrows in each track highlight TSS. At the bottom,
thick arrowheads indicate direction of transcription. b) FANTOM5
analysis of mDA-OR expression in mouse tissues and various brain
regions. c) qRT-PCR of OR transcripts expressed in various brain
regions. Normalized mRNA levels (ΔΔCt) of Olfr287, Olfr316 and Olfr558
in mouse tissues. Hippocampus was used as reference and set to 1.
OE, olfactory epithelium; MB, ventral midbrain; CTX, cortex; OB,
olfactory bulb; CB, cerebellum; HC, hippocampus. Data indicate
mean ± st dev and are calculated on three independent experiments.
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putative human OR TSS (Figure 5a, left panel), with two
of them falling in the same OR locus (OR10J7P). Main
TSS could be found at the exact positions of annotated
RefSeq (OR7A5, OR51E1 and OR51E2), further upstream,
between -500 bp and -2000 bp (OR8G5, OR2H4P, OR52K2
and OR9A2), in the intragenic region (OR9A4, OR56B3P,
OR10AB1P) or at the 3′-end (OR4K6P). For two of them,
the position was far upstream (>5000 bp) of the annotated
gene and thus not further investigated (OR10J7P and
OR4C15).
As a second approach, we applied sequence similarity
comparison with mouse mDA-OR. To this purpose we
performed a multiple sequence alignment between human
ORs present in the OlfactionDB, for which functional
validation exists, and the validated mouse mDA-ORs.
Based on this alignment, a maximum-parsimony phylo-
genetic tree was then built (Additional file 9: Figure S7).
We found that highest similarities could be measured
between Olfr558 and human OR51E1 (94% sequence
identity), Olfr166 and OR2L13 (85% identity), Olfr287
and OR10AD1 (81% identity) and Olfr316 and OR2AK2
(76% identity).
We then took advantage of FANTOM5 data for
human SN to monitor expression of candidate human
OR genes using tag counts across the whole locus of
interest (sum5end). We thus found evidence of transcrip-
tion for most of the selected human ORs with TPM values
ranging from 31.03 to 0.12 (Figure 5a). Negative counts
were present for those ORs for which TSS coordinates
were poorly found (OR10J7P and OR4C15) and those with
weaker homology (OR10AD1 and OR2AK2). OR2L13 was
the top expressed OR. OR51E1, identified by both ap-
proaches, could also be found in human SN, although at
lower level. We then validated their expression by success-
fully cloning OR2L13 cDNAs from SN RNA (Figure 5b)
and by detecting two bands of the expected molecular
weight by using an anti-OR51E1 antibody on human SN
extracts (Figure 5c).
Figure 4 (See legend on next page.)
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Figure 4 Selected odors activate mDA-ORs expressed in heterologous cells as well as primary mDA neurons. a) Olfr287 was transiently
transfected in HEK cells in combination with pCRE-SEAP. After transfection, cells were pulsed with the indicated odor molecules at 600 μM
concentration. DMSO was used as negative control (cntrl). mDA-OR activation was measured with fluorimetric assay on culture medium. Odor
response was calculated as fold-increase relative to control value. Data indicate mean ± st dev and are calculated on n = 4 independent experiments.
b) Cells were transfected as in a) and pulsed with increasing concentrations of R-carvone, S-carvone, menthone and decanoic acid. Ringer’s solution
or DMSO was used as control (cntrl). mDA-OR activation was calculated as in a). Data indicate mean ± st dev and are calculated on at least three
independent experiments. *, p < 0.05; **, p < 0.01; *** p < 0.001. c) Ca2+ dynamics in primary DA neurons dissociated from the ventral midbrain of
TH-GFP mouse. Normalized fluorescence ratio changes (340/380 nm) were measured in DA neurons loaded with Fura-2 AM and challenged with
bath-applied odor mixture composed by 16 odorants at 200 μM each (recordings from N ≈ 30 neurons and repeated in n = 2 independent
experiments). Images are presented in pseudocolour scale, as indicated. GFP fluorescence of DA neurons is shown. Scale bars indicate 10 μm.
d) Experiment as in c). Primary neurons were stimulated with (R)- and (S)-carvone mixture at 600 μM each.
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moter expression atlas (N = 988 libraries) showed that
the repertoire of OR identified in the SN has a complex
pattern of expression (Additional file 10: Figure S8).
Liver is the only organ where none of the analyzed OR
is expressed. OR2L13 was strongly enriched in the brain,
while OR51E1 was highly expressed in prostate. Their
TSS usage is shown in Figure 5d. qRT-PCR analysis of
human tissues validated these findings (Figure 5e).
For functional assay, OR2L13 was then transiently
expressed in heterologous HEK 293 cells in combination
with CRE-SEAP reporter plasmid to monitor SEAP
quantity in response of odor stimulation. Membrane
localization and size of the ectopically expressed protein
were monitored by immunocytochemistry and western
blot (Additional file 11: Figure S9a and b). Statistically
significant responses were elicited by carvone enantiomers
and eugenol although at detection limits (Additional
file 11: Figure S9c and d).
Given their expression at the site of neurodegenera-
tion, we monitored OR transcripts in SN from 11 PD
and 10 control post mortem brains. OR2L13 and
OR51E1 expression were analyzed together with a subset
of ORs that were previously demonstrated to be down-
regulated in the cortex of PD patients [19]. To achieve
high sensitivity and specificity, we set up TaqMan assays
for each OR gene transcript. First, we could measure the
expression of this panel of ORs in the SN of several indi-
viduals (controls), further implementing the repertoire
of OR transcripts in this brain region (Figure 5f ). Then,
we found that OR gene expression is down-regulated in
the SN of PD patients, as recently reported for the cortex
[19], with the only exception of OR51E1, whose decrease
is not significant. Down-regulation of human ORs in PD
patients cannot be solely due to neuronal cell loss since in
the same samples we could detect either unchanged or
up-regulated levels of some taste receptors (TASR) [20]
that were found expressed in the SN (Additional file 12:
Figure S10).
Altogether, our results highlight the expression of a
repertoire of OR genes in human SN and their dysregu-
lation in PD.Discussion
In the main OE the detection of a vast repertoire of vola-
tile compounds (odors) is accomplished by a large family
of ORs on the surface of the cilia of OSNs. Odorants bind-
ing to ORs activate G proteins and initiate downstream
signaling that leads to Ca2+ influx and ultimately to the
perception of smell.
Each mature OSN in the OE is thought to express only
one allele of a single OR gene—monoallelic and monogenic
expression, respectively. A given OR gene is expressed in a
mosaic or punctate pattern of OSNs within a characteristic
zone of the OE. The transcriptional mechanisms that
underlie this extraordinary restriction in gene expression
remain unclear. To address this issue, by applying nanoC-
AGE to mouse OE, we have previously associated TSSs to
955 mouse OR genes, thereby defining a comprehensive
picture of their promoter map at a single-base resolution.
In contrast with the archetype of the broad shape of >75%
of mammalian promoters, OR genes have sharp pro-
moters exhibiting a dominant TSS [13].
A distinctive feature in the topographic organization
of the olfactory system is that ORs also plays an instruct-
ive role in the axonal convergence of OSN into the ol-
factory bulb (OB). This function is supported by genetic
experiments and by the expression of the OR on the
axon termini of the OSN. OR at the growth cone of
OSN are capable of binding odors and are coupled to
cAMP synthesis and Ca2+ influx through cyclic nucleo-
tide gated (CNG) channels. This suggests a potential role
of OR activation in axonal convergence and sensory
map formation [17,21].
Interestingly, ORs have been also found to reside in
tissues other than those involved in olfaction [22-24].
Several distinct ORs are expressed predominantly or
exclusively in spermatogenic cells, where they mediate
sperm chemotaxis [25]. Selected ORs accumulate in
prostate cancer to inhibit proliferation [26]. Olfr16, a
well-characterized receptor in mouse, controls chemo-
sensing and motility in sperm [27] as well as regeneration,
cell adhesion and migration in muscle [28]. Single ORs
were found expressed in layer II pyramidal neurons in the
occipital lobe and tightly controlled during development,
Figure 5 (See legend on next page.)
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Figure 5 A subset of human ORs is expressed in SN and down-regulated in PD post mortem brains. a) FANTOM5 CAGE data in human SN
samples. Heat map graphical representation of human ORs expression in adult and neonate samples, as indicated. List of human ORs identified
by genomic approach (left) and by homology search (right). b) Complete open reading frame for human OR2L13 was cloned from RNA extracted
from SN of two individuals (SN#1 and SN#2), not affected by neurodegenerative disorders (controls). c) Proteins were extracted from post mortem
material. Western blot analysis was performed with anti-OR51E1 antibody. Protein extract from SH-SY5Y cells was included as negative control.
β-actin was used as loading control. Images are representative of n = 2 independent experiment with n = 2 independent SN samples. d) ZENBU
genome browser view of CAGE signals for OR2L13 and OR51E1 in human SN. Genomic coordinates are shown on top and scale of expression
values (TPM) on the left. Black arrows in each track highlight transcription start sites (TSS). At the bottom, thick arrowheads indicate direction of
transcription. e) qRT-PCR validation of human mDA-ORs expression in human tissues. A panel of human RNAs from various tissues was used to
validate atypical expression of OR2L13 and OR51E1. Brain was arbitrarily set as 1. f) qRT-PCR of SN from control and PD post mortem brain
samples. *p < 0.05; **p < 0.01; ***p < 0.001.
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cently, by taking advantage of mRNA-Seq data of 16 hu-
man tissues available from Illumina Body Map project 2.0,
111 OR genes were shown expressed outside of OE.
Interestingly, OR51E1 and OR2W3 were expressed in all
the tissues analyzed while others showed a more restricted
pattern with several examples of expression in only one
tissue [23]. Therefore, it is becoming evident that non-
olfactory cells can hijack ORs as a general signaling path-
way to achieve other cell-specific functions.
Here we show that multiple ORs are expressed by
mouse mDA neurons, a cell system that is involved in
movement control and reward behavior. Interestingly,
OR gene expression is also present in other regions as
well as outside of the mouse brain. Global transcriptome
analysis, cDNA full-length cloning and quantitative
RT-PCR indicate that OR transcripts can be also found in
human SN.
NanoCAGE [12] is a next-generation sequencing tech-
nology for unbiased 5′-end transcriptome profiling and
have provided measurement of the expression level of
ORs transcripts along with the precise definition of their
TSSs from purified mDA cells. Being a single-nucleotide
resolution technology, it greatly differs in terms of quan-
titative and qualitative output from microarray platforms
or from PCR screenings based on degenerated oligonu-
cleotides. While the expression of a significant number
of Olfrs has been confirmed both with nanoCAGE ana-
lysis of LCM-purified cells and RT-PCR from MB, some
discrepancies have been noticed that may be explained
as follows. First, A9 and particularly A10 DA cell groups
are highly heterogeneous. On the basis of morphology
and connectivity 13 different A10 neuronal cell types
have been described. The low associated TPM scores
may thus be interpreted as RNAs transcribed by a spe-
cific DA subtype leading to expression under detection
threshold in total MB analysis. This has been already
shown by the comparison of the DeepCAGE data with
in situ hybridization for the hippocampus [30] and re-
ported for ORs in the gut, where they were expressed
exclusively in gastrointestinal enterochromaffin cells,
which constitute only a minor proportion of the totalintestinal epithelium [31]. Importantly, nanoCAGE data
do not offer any description of the anatomy of the tran-
script. Gisselmann and collegues [23] showed that human
ORs give raise to a plethora of transcripts with surprising
features: unexpected internal introns, truncated or
chimeric RNAs with adjacent genes and 5′ ends derived
from distant, previously undescribed TSSs. While we
have provided full-length cDNAs of validated mDA-ORs
cloned from MB, a detailed analysis of transcript anatomy
for every single gene presenting nanoCAGE tags will as-
sess this important issue.
As in OE, validated mDA-ORs present sharp promoters
in mDA cells. Most importantly, the very same TSS is
often used in both tissues. Sharp promoters without CpG
islands are often bound by TFs within a constrained
spacing range. ORs promoters are no exceptions showing
positional preferences for specific motifs such as for
Mef2a, EBF1/HOX and SOX [13]. This transcription fac-
tor binding site code can also be relevant for their tran-
scriptional control in mDA cells as well as in the brain.
This may suggest that the promoter architecture of ORs
may be under evolutionary pressure to drive transcription
both in OE and in other tissues strongly challenging the
idea that OR expression outside OE is “atypical” or
“ectopic”.
Deorphanization of ORs is a very important task that
has been attempted at different scales. While virtual
High-Throughput Screening (HTS) has been successful
to identify novel ligands [32], large efforts have been
dedicated to the optimization of heterologous expression
systems for efficient ectopic membrane localization of
ORs and detection of responses to odor-like molecules.
Among the most successful HTSs, 93 odorants have been
tested on 464 ORs expressed in heterologous cells identi-
fying agonists for 52 mouse and 10 human ORs [33,34].
In this study, the screening has been limited to 16 po-
tential ligands and 5 ORs cDNAs. Odor-like molecules
have been chosen for representing the major chemical
moieties and putative ligands proposed on the basis of
sequence similarity between mDA-ORs and those present
in the OlfactionDB plus chemical ligands identified by
chemoinformatic approaches.
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responses, analysis of Olfr166 and Olfr558 were limited
by their low expression at the cell membrane.
Despite these limitations we have been able to identify
the first odor-like molecule that act on mDA cells.
Carvones are monocyclic monoterpene with antioxi-
dant, antimicrobial, anticonvulsant, and antitumor activ-
ities. (R)-(−)-carvone is the main constituent of spearmint
oil (Mentha spicata var. crispa) while (S)-(+)-carvone is a
major component of caraway and dill seed oils. We prove
that they elicited a strong response in Olfr287 expressed
in the heterologous system and that they triggered Ca2+
responsiveness in solitary mDA neurons. A formal prove
that mDA neurons response is mediated by Olfr287
requires further experiments that are beyond the scope of
this work.
These results suggest a potential role of OR activation
in mDA physiology. However, the identity of the endogen-
ous ligands for mDA-ORs remains unknown.
A further optimization of heterologous expression of
mDA-ORs and a largest repertory of odor-like molecules
will probably lead to the discovery of additional agonists
at mDA cells and therefore to new molecular tools to
manipulate mDA subtypes’ activities.
This concept can be extended to any ORs expressed
outside the OE and to any expressing neuronal cell
types. Odor-like molecules may thus represent new op-
portunities for developing neuroactive drugs that act on a
defined repertoire of cells. If coupled with radioisotopes,
they might also serve as probes for in vivo imaging.
Since in the OE the functional activation of ORs
requires Gαolf and Adcy3, it is important that we de-
tected the expression of these signaling molecules in
mDA neurons as well. Many evidences position Gαolf
at a crucial crossroad of the dopaminergic system in
health and disease [35]. So far Gαolf–mediated pheno-
types have been interpreted for its ability to mediate
dopamine receptor 1 signaling in striatal medium spiny
neurons [36]. According to our work, it will be also
important to assess the contribution of signaling initi-
ated at ORs.
Albeit limited by the small size of patients’ samples
available for this study, we have shown that the large
majority of human ORs expressed in SN are down-
regulated in PD post mortem brains. Interestingly, in the
same PD samples TASR are up-regulated, thus suggest-
ing that OR down-regulation is not entirely due to neur-
onal cells loss. For some of the ORs expressed in human
SN such as OR51E1, OR2J3 and OR51E2, HTS have led
to the identification of potential agonists. It will be thus
interesting assaying, respectively, nonanoic acid and
butyl butyryllacetate, cys-3-hexen-1-ol and cynnamalde-
hyde as well as propionic acid for their activities on
human DA cells.Early-stage PD has been associated to a significant
smell dysfunction in some monogenic forms as well as
in sporadic PD cases, with a prevalence of approximately
90% [37]. Unlike cells in the SN, periglomerular DA cells
of the olfactory bulb do not degenerate but increase in
number with a concomitant induction of TH expression.
The basis for olfactory dysfunction in PD is currently
unknown. It remains to be determined whether ORs
down-regulation in SN has a role in the olfactory dys-
function observed in PD patients [37].
Conclusion
By nanoCAGE transcriptome profiling we demonstrate
that a subset of ORs is expressed in isolated A9 and A10
mDA neurons. In these cells, odor-like stimuli are able
to evoke Ca2+−signals. Expression of ORs is also detected
in human SN, the site of neurodegeneration in PD, and
is found regulated in PD post mortem brains.
ORs might thus contribute to the normal physiology
of mDA neurons in mammals and potentially be target
of pharmacological manipulation with odor-like mole-
cules in disease.
Methods
Animals
All animal experiments were performed in accordance
with European guidelines for animal care and following
SISSA Ethical Committee permissions. Mice were housed
and bred in SISSA non-SPF animal facility, with 12 hours
dark/light cycles and controlled temperature and humid-
ity. Mice had ad libitum access to food and water.
LCM was performed on 12 weeks-old female TH-GFP/
21-31 mice [14] (n = 3). C57BL/6 female mice (n = 5),
12 weeks old, were used for in situ hybridization and im-
munohistochemistry experiments. Intra-cardiac perfusions
were done under total anaesthesia.
Isolated mDA neurons were prepared from P9-P10
TH-GFP pups (n = 8).
NanoCAGE library preparation and data analysis
Synthesis of nanoCAGE libraries, sequencing and bio-
informatic analysis were carried out as in Plessy et al.
[12,13] and Lazarevic et al. (Lazarevic D, Bertin N, Franke
V, Vlachouli C, Caiazzo M, Plessy C, Akalin A, Vatta P,
Simone R, Roncaglia P, Daub CO, Faulkner GJ, Broccoli V,
Lenhard B, Carninci P, Gustincich S: The promotorome
of adult dopaminergic neurons of the mouse Substan-
tia Nigra identifies new gene networks for cell conver-
sion. Submitted).
PCR, quantitative RT-PCR (qRT-PCR) and cloning
Total RNA was extracted from cells and tissue using
Trizol (Invitrogen) according to manufacturer’s instruc-
tion. RNA was extracted from LCM- purified cells with
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ples were treated with DNAseI (Ambion). A panel of
purified DNAse-treated human tissue-specific RNAs was
obtained from Life Sciences (FirstChoice® Human Total
RNA Survey Panel). cDNA was prepared from 1 μg of
RNA using the iSCRIPT™ cDNA Synthesis Kit (Bio-Rad)
according to manufacturer’s instructions. Non-quantitative
RT-PCR was performed with standard protocol. qRT-PCR
was performed in triplicate using SYBR-Green PCR Master
Mix (Applied Biosystem) and an iCycler IQ Real time PCR
System (Bio-Rad). Relative gene expression was calculated
with ΔΔCt method.
A heat map graphical representation of rescaled nor-
malized fold expression (ΔΔCt/ΔΔCtMAX) was obtained
using the Matrix2png software (http://www.bioinformatics.
ubc.ca/matrix2png/).
Full-length mDA-ORs were cloned from ventral mid-
brain and inserted into pcDNA3.1-Rho vector kindly pro-
vided by Prof. Liberles. Cloned mDA-ORs were verified
upon sequencing.
The complete list of oligonucleotides used for PCR
and RT-qPCR is in Additional file 13: Table S3. All
amplicons were sequenced.In situ hybridization (ISH)
Sense and antisense probes were generated by in vitro
transcription from the cDNA encoding Olfr287, Olfr316
and Olfr558. Riboprobe synthesis and hybridization were
performed as in Carrieri et al. [16]. Probes were labelled
with biotin (BIO-labelling mix, Roche) and were used
at a concentration of 4 μg/ml at 60°C for 16 h. List
of primers used for generating probes is in Additional
file 13: Table S3.Phylogenetic tree and in silico ligand identification
The evolutionary history was inferred using the Maximum
Parsimony method. The MP tree was obtained using the
Close-Neighbour-Interchange algorithm, with search level
0 in which the initial trees were obtained with the random
addition of sequences (10 replicates). The analysis in-
volved 87 amino acid sequences. All positions containing
gaps and missing data were eliminated. There were a total
of 285 positions in the final dataset. Evolutionary analyses
were conducted using MEGA5 [38]. The structures of
odorant ligands and their cognate receptors were taken
from the OlfactionDB database (http://molsim.sci.univr.it/
OlfactionDB). Structurally similar ligands were identified
by virtual screening of the ‘ligand.info’ database [39].
This database contains <1,160,000 ligands. Structural
similarity was estimated by the Tanimoto’s equation
using the ROCS algorithm in the OpenEye suite of pro-
grams (www.eyesopen.com). For each template, the 100
best hits were selected.Cell lines and transfection
Human embryonic kidney 293 cells (HEK 293) were grown
as in Carrieri et al. [16]. MN9D-Nurr1Tet-On cells (iMN9D)
[40] were kindly provided by Professor Perlmann and
maintained as in Biagioli et al. [15].
Transfection was performed with Fugene HD (Promega)
following manufacturer’s instructions.
Western blot
48 h after transfection, cells were lysed in Lysis Buffer
(20 mM Tris–HCl pH 7.5, 150 mM NaCl, 1 mM EDTA,
1% TritonX-100). The lysates were incubated 30′ on ice
and clarified by centrifugation at 13.000 rpm for 20′.
Cell pellets were resuspended in Sample Buffer 2×. Total
protein lysates from mouse organs were prepared by
homogenization in Lysis Buffer (140 mM NaCl, 5 mM
KCl, 5 mM NaHCO3, 1.2 mM Na2HPO4, 1 mM MgCl2,
20 mM HEPES pH 7.4, 10 mM dextrose, 1.8 mM
CaCl2). Proteins from human samples were extracted
using Trizol reagent and following manufacturer’s in-
structions. Equal amount of proteins were separated in
10% SDS-polyacrilamide gel and transferred to nitrocel-
lulose membrane. Immunoblotting was performed with
the following primary antibodies: anti-Rhodopsin tag
(Novus Biological), anti-βactin (A5441, Sigma) and anti-
OR51E1 (Thermo Scientific). Signals were revealed after
incubation with secondary antibodies conjugated with
horseradish peroxidase by using Immobilon (Millipore).
Immunohistochemistry and immunocytochemistry
Immunohistochemistry was performed as previously
described on 16 μm-thick cryo-slices prepared from
12 weeks old C57BL/6 mice (n = 3) [15]. Primary anti-
bodies anti-OR51E1 1:1000 (Novus Biologicals) and
anti-TH 1:1000 (SIGMA) were used.
For immunocytochemistry experiments, 48 h after
transfection, cells were fixed in 4% paraformaldehyde for
10 minutes, washed with PBS and treated with 0.1 M
glycine for 4 minutes. After washing, cells were blocked
in the non-permeabilizing buffer (0.2% BSA, 1% NGS, in
PBS). Cells were incubated with anti-Rho tag antibody
1:1000 in blocking solution for 90 minutes at room
temperature. After washes in PBS, cells were incubated
with secondary antibody Alexa Fluor-488 (Molecular
Probes-Invitrogen,) for 1 h. Nuclei were visualized with
1 μg/ml DAPI. Cells were mounted with Vectashield
(Vector laboratories) and analyzed at confocal microscope
(Leica).
mDA-ORs functional assays
Functional assays were performed as described previously
[41]. Briefly, 80,000 HEK 293 cells were plated in 24-well
plates and co-transfected with 400 ng of pCDNA3.1-Rho
mDA-OR construct and 400 ng of pCRE-SEAP reporter
Grison et al. BMC Genomics 2014, 15:729 Page 13 of 16
http://www.biomedcentral.com/1471-2164/15/729plasmid. 16 hours after transfection cells were treated with
odors for 48 hours. SEAP was detected using GreatEscape
SEAP kit (Clontech) according to manufacturer’s instruc-
tions. Fluorescence was measured with a Fluorimeter
Spectramax M5 multi-mode microplate reader. For test
compounds, see Additional file 6: Table S2.
Calcium Imaging in primary mDA neurons
Isolation of mDA neurons was performed as described pre-
viously [15,42]. Briefly, ventral midbrain was isolated and
the pieces containing the SN were enzymatically dissoci-
ated with Papain (SIGMA) under continuous oxygenation
(5% CO2 and 95% O2 gas mixture) with slow stirring at
35°. After 40 minutes, the reaction was stopped with 1 mg/
ml trypsin inhibitor (Sigma) and the pieces were triturated
by using p1000 tip and glass pasteur pipette. The cell sus-
pensions were centrifuged at 1000 rpm for 3 min and the
pellet was resuspended. Dissociated neurons were plated
on the slides coated with poly-lysine (1 mg/ml, SIGMA).
After 3 hours, Ca2+ imaging was performed.
Dissociated neurons were incubated with 8 μM fura-
2 AM, 80 μg/ml Pluronic F127 and sulphinil pyrazone
250 μM (Molecular Probes) for 20 minutes.
Neurons were constantly perfused in Ringer’s solution
(3 ml/min) except during stimulation applied for 4-10s.
Stimuli were a mixture of odors (citronella, citralva,
(+)-carvone, (−) carvone, menthone, geraniol, eugenol,
acetophenone, benzyl alcohol, benzaldeheyde, propionic
acid, heptanoic acid, IBMP) or a mixture containing both
R- and S-carvone enantiomers. All odorants are from
Sigma Aldrich.
Changes in intracellular Ca2+ were visualized using
380 nm and 340 nm excitation filters and 510/40 nm
emission filter and were acquired every 3 s. using a CellR
system. Changes in fluorescence (340 nm /380 nm) were
expressed as R/R0 where R is the ratio at time t and R0
is the ratio at time = 0 s. Responses (%) were evaluated
as ΔR/R0 × 100 where ΔR = R-R0.
Bioinformatic analysis of olfactory receptors in FANTOM5
collection of human libraries
We selected windows of 200 bp on the mouse genome,
centered on transcription start sites of olfactory receptors
detected using nanoCAGE [13] and “lifted” their coordi-
nates over the human genome version 19 [18] to obtain
putative promoters for human olfactory receptors. For
three pairs of receptors, Olfr55/Olfr239, Olfr216/Olfr317,
and Olfr1507/Olfr1508, the lift produced the same coordi-
nates, and we discarded each second member of the pairs.
The expression levels of these putative human OR pro-
moters was calculated by counting the number of CAGE
tags from the FANTOM 5 promoter expression atlas [11]
starting in these windows, using scripts available upon
request, based on tabix [43] and bedtools [44]. Out of 499regions, 100 had more tags than the 3rd quartile and 15
had more than 100 tags, an arbitrary cutoff that we chose
after visual inspection of the data in FANTOM5’s instance
of the ZENBU genomic browser [45], which showed that
lower scores were enriched for apparently spurious accu-
mulation of tags near pseudogenes.
Human samples
Brain tissue was obtained from the Institute of Neuro-
pathology HUB-ICO-IDIBELL (University Hospital of
Bellvitge- IDIBELL Foundation) Bio-Bank following the
guidelines of Spanish legislation on this matter and in
compliance with the Helsinki Declaration (http://www.
wma.net/en/30publications/10policies/b3/index.html).
Samples were dissected at autopsy with the informed
consent of patients or their relatives and the institutional
approval of the local Ethics Committee (HUB-ICO/CEIC),
signed by Dr. Enric Sospedra Martinez.
Cases analyzed included 10 controls and 11 PD cases
[19]. Samples of SN were dissected at the time of
autopsy, and immediately frozen and stored at −80°C
until use. The purification of RNA was carried out with
RNeasy Lipid Tissue Mini Kit (Qiagen, DE) following
the protocol provided by the manufacturer. During puri-
fication, samples were treated with RNase-free DNase
Set (Qiagen, DE) to avoid later amplification of genomic
DNA. The concentration of each sample was obtained
from A260 measurements with Nanodrop 1000. RNA
integrity was tested using the Agilent 2100 BioAnalyzer
(Agilent, US). The retrotranscriptase reaction was car-
ried out using a High Capacity cDNA Archive kit
(Applied Biosystems, US) following the protocol pro-
vided by the supplier. Parallel reactions for each RNA
sample were run in the absence of MultiScribe Reverse
Transcriptase to assess the degree of contaminating
genomic DNA.
TaqMan PCR assays for each gene were performed in
duplicate on cDNA samples in 384-well optical plates
using an ABI Prism 7900 Sequence Detection System
(Applied Biosystems, US). For each 20 μl TaqMan reac-
tion, 9 μl cDNA was mixed with 1 μl 20× TaqMan Gene
Expression Assays and 10 μl of 2× TaqMan Universal
polymerase chain reaction (PCR) Master Mix (Applied
Biosystems, US). The reactions were carried out using the
following parameters: 50°C for 2 min, 95°C for
10 min, and 40 cycles of 95°C for 15 s and 60°C for
1 min. Finally, all TaqMan PCR data were captured
using the Sequence Detector Software (SDS version
1.9, Applied Biosystems, US). Probes used in this study
are listed as follows:
OR2J3: ACCGCCAAGTAGATCACTTTTTCTG
OR52L1: CTCAGCAGATCCGCCAGCGAGTGCT
OR51E1: TACGGTTGAGCCTCTACCTGCCTGG
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OR2T33: AACGGTGGCTGGGGACGTGTGTAAA
OR11H1: CACTGGGAGACATAAGGCCTTCTCT
OR2D2: GTGAGGCCCCTGCACTATTGATCTT
OR4F4: TATACACACTGAGGAACAAAGACAT
TAS2R4: CACCATTTACTGTGGCCTTCATCTC
TAS2R5: TTTCTTGTTTCCTCTGGGATGCTGA
TAS2R10: ACCACAGCCATCTATCCCTGGGGTC
TAS2R13: CACCATTTACTGTGGCCTTCATCTC
TAS2R14: TTTGTCCCTGGCAATGTTTCTTCTC
TAS2R50: AGTCCTAGGAGGCTGCGGAATGACC
Samples were analyzed with the double delta CT
(ΔΔCT) method. Delta CT (ΔCT) values represent
normalized target gene levels with respect to the in-
ternal controls (GUSB, Glucuronidase beta: GCTAC-
TACTTGAAGATGGTGATCGC; XPNPEP1, X-prolyl
aminopeptidase 1: CAAAGAGTGCGACTGGCTCAA
CAAT; and AARS, alanyl-tRNA synthetase: GCAAAAT
TTGGGGCTGGATGACACC). Reference genes were
selected because they are very efficient in replicating
microarray target gene expression in human post mor-
tem brain tissue. ΔΔCT values were calculated as the
ΔCT of each test sample minus the mean ΔCT of the
calibrator samples for each target gene. The fold
change was calculated using the equation 2(−ΔΔCT).
Results were subjected to statistical analysis as de-
scribed below.Statistical analysis
Statistical analyses were performed with paired two-
tailed Student’s t-test. Results are mean (n ≥3) ± standard
deviation (s.d.). Number of replicas in each experiment
is further described in figure legends. qRT-PCR data on
human samples were analyzed by two-way ANOVA
followed by Student’s t-test when required. Differences
between mean values were considered statistically signifi-
cant * p < 0.05; ** p < 0.01; *** p < 0.001.Data access
NanoCAGE sequences have been submitted to the DNA
DataBank of Japan Sequence Read Archive (DRA) under
accession number DRA000475. Data will be available
upon release of an accompanying manuscript (Lazarevic
D, Bertin N, Franke V, Vlachouli C, Caiazzo M,
Plessy C, Akalin A, Vatta P, Simone R, Roncaglia P,
Daub CO, Faulkner GJ, Broccoli V, Lenhard B, Carninci P,
Gustincich S: The promotorome of adult dopaminergic
neurons of the mouse Substantia Nigra identifies new
gene networks for cell conversion. Submitted). This
work is part of the FANTOM5 project. Data downloads
and genomic tools are summarized here http://fantom.gsc.
riken.jp/5/.Additional files
Additional file 1: Table S1. List of mDA-ORs. Complete list of ORs
identified by nanoCAGE in A9 and A10 neurons. Expression values (TPM)
measured for each receptor is indicated in the appropriate column. No
expression is also shown (−). Results from non-quantitative PCR validation
in RNA extracted from total midbrain (MB) or from laser capture
microdissected (LCM) neurons are indicated (−, negative; +, positive; NT,
not tested).
Additional file 2: Figure S1. Expression of OR-mediated signal
transduction elements in mouse mDA neurons. a) nanoCAGE datasets.
UCSD Genome browser view of Gαolf and Adcy3 expression in A9, A10.
Tracks from nanoCAGE of olfactory epithelium (from Plessy et. al,
Genome Research, [13]) are included for comparison (OE). Initiation of
annotated RefSeq is shown. Black arrows indicate transcription start sites
(TSS). Genomic coordinates are shown on top and expression values (TPM)
on the left. Direction of transcription is indicated by a thick arrowhead at
the bottom of each panel. b) FANTOM5 mouse datasets. Zenbu genome
browser view of Gαolf and Adcy3 expression in neurons from SN and in
olfactory brain. TPM values are shown on the left.
Additional file 3: Figure S2. Specificity of expression of ORs in mDA
neurons. Specificity of expression of Olfr287, Olfr316 and Olfr558
transcripts (green) by ISH in A9 and A10 DA neurons is verified with
control sense probes. DA neurons in SN are visualized by anti-TH
immuno-staining (red). Nuclei are shown in blue (DAPI). Scale bars indicate
20 μm. Data are representative of n = 3 independent experiments.
Additional file 4: Figure S3. Endogenous OR protein is expressed in
mDA neurons and in mouse brain. a) Anti-OR51E1 antibody recognized
Olfr558 (green) expressed in heterologous HEK 293 cells. Immunofluorescence
in non-permeabilizing conditions. Nuclei are visualized with DAPI (blue). Scale
bars indicate 38 μm. White arrows highlight transfected cells. b) Endogenous
OR protein is detected in A9 and A10 mDA neurons and in the cortex. mDA
neurons were visualized with anti-TH (red) and OR with anti-OR51E1 specific
antibody (green). Nuclei are stained with DAPI (blue). Scale bars indicate
20 μm. Images are representative of n = 3 independent experiments.
Additional file 5: Figure S4. Overexpression of mDA-ORs in iMN9D
and HEK 293 cells. mDA-ORs were cloned from the ventral midbrain into
pCDN3.1-Rho tag vector. Plasmids were transiently transfected in iMN9D
cells. Expression of mDA-ORs (olfr166, olfr287, olfr316, olfr558 and olfr1344) was
verified by western blotting (n = 5) (a) and immunofluorescence (n = 3) (b)
with anti-Rho antibody. pCDN3.1- empty vector and S6 OR expressing plasmid
were used as negative and positive controls, respectively. c) HEK 293 cells were
transiently transfected with the indicated mDA-ORs and tested as in b.
Additional file 6: Table S2. List of odors. Complete list of odors used
in this study. Odor formulation and concentration of stock solution are
indicated.
Additional file 7: Figure S5. Evolutionary and chemoinformatics
characterization of mDA-ORs. a) Model of phylogenetic tree distribution of
mDA-ORs. b) Putative ligands for each receptor based on ligands of the clos-
est homologue in the phylogenetic tree and by a chemoinformatic search.
Additional file 8: Figure S6. Analysis of mDA-ORs responses to
selected odors. mDA-ORs were transiently transfected in HEK cells in
combination with pCRE-SEAP. After transfection, cells were pulsed with
odor molecules at 600 μM concentration. Nonanoic acid was used at
1 mM. Ringer’s solution or DMSO was used as control. mDA-OR activation
was measured with fluorimetric assay on culture medium. mDA-ORs used
in this assays (olfr166, olfr316, olfr558 and olfr1344) are indicated. Data
indicate mean ± st dev and are calculated on four independent
experiments.
Additional file 9: Figure S7. Sequence homology strategy for human
mDA-ORs. Model of phylogenetic tree distribution of mouse mDA-ORs
for the identification of human homologues.
Additional file 10: Figure S8. Expression of human mDA-ORs in
selected human FANTOM5 hCAGE libraries. Color-coded representation
of OR expression in human FANTOM5 hCAGE libraries. Values are
expressed in tag per million (TPM). SN libraries are in red; tissue libraries
that were validated by qRT-PCR are in blue.
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http://www.biomedcentral.com/1471-2164/15/729Additional file 11: Figure S9. Analysis of OR2L13 response to selected
odors. Expression of human OR2L13 in HEK cells was verified by
immunofluorescence (a) and western blotting (b) with anti-Rho antibody.
pCDN3.1-empty vector and S6 OR expressing plasmid were used as
negative and positive controls, respectively. For functional assays, OR2L13
was transiently transfected in HEK cells in combination with pCRE-SEAP.
After transfection, cells were challenged with odor molecules at 600 μM
concentration (c) or at the indicated quantities (d). Ringer’s solution or
DMSO was used as control. mDA-OR activation was measured with
fluorometric assay on culture medium. Data indicate mean ± st dev and
are calculated on two independent experiments.
Additional file 12: Figure S10. A subset of human Taste Receptors is
regulated in PD. qRT-PCR of SN from control and PD post mortem brain
samples. Data indicate mean ± stdev. *p < 0.05.
Additional file 13: Table S3. List of primers. Complete list of
oligonucleotides used in this study for non-quantitative PCR, quantitative
RT-PCR, cloning and in situ hybridization.
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